We started buying Gilead Sciences over 1 year ago. Over a week ago we sold it. Our original thesis on Gilead was 5-fold: 1) a stabilization of its HCV business (which had been declining), 2) its leading HIV treatments, 3)… Read More
AMM Dividend Letter 35: Expectations Versus Reality & Gilead (GILD)
Our 2017 stock market prediction was wrong! From Issue 32 The S&P 500 will return between -26% and 20%! The total return for the S&P 500 in 2017 was 21.82%. In our defense, the prediction was only within a 95% confidence range and… Read More